For both subcutaneously or intravenously injected B16-OVA cells, we demonstrated that adoptively transferred 2'3'-cGAMP-stimulated tumor Ag-specific TH9 cells secreted more IL-9 and triggered better antitumor immunity compared to controls without STING agonists [55]. Here, STING1 is linked to neoplasm.